| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz, MD, FACP, has been appointed to its Board of Directors....
Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance...
PR Newswire, San Diego, June 24, 2020 - Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination...
SAN DIEGO, May 28, 2020 - Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader...
Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that the Company recently held a collaborative and productive...
